Analyst Perspectives on Supernus Pharmaceuticals Stock
Supernus Pharmaceuticals (NASDAQ:SUPN) has received ratings from 5 analysts in the past three months, reflecting a mix of bullish and bearish views.
Average 12-month price targets are $54.8, with a high of $65.00 and a low of $40.00, marking a 31.1% increase from the previous average of $41.80.
- Average price target: $54.8
- High estimate: $65.00
- Low estimate: $40.00
Author's summary: Analysts provide insights into Supernus Pharmaceuticals stock.
More News
- Silver Price Outlook – Silver Continues to Defy Gravity
- My Favourite Thing About Doing a Monthly Progress Review and Staying Motivated
- Silver Price Surges Past $58, Setting a New Record High
- Delhi CM reviews progress on 53-km Yamuna cycle track project
- Harry Bryant on Getting Locked Up in Indo, Metal in the Leg, and Ritual Vision’s Wild Creative Ride
- Lomography: Explore Analog and Experimental Photography Techniques
- Georgia Power Rates May Increase as PSC Considers Data Center Expansion, Analysts Say
- Reader photos of the year 2025: Share your best shot and join the showcase
- Silver Today Rate, December 1: Silver price today in India, Delhi, Hyderabad, Bangalore, Chennai, Mumbai and other silver rate list
- Georgia Power defends proposal for data centers, disputes $20 monthly bill hike claim